Vanda Pharmaceuticals Inc. (VNDA)

Market Cap	306.71M
Revenue (ttm)	177.60M
Net Income (ttm)	-4.89M
Shares Out	58.20M
EPS (ttm)	-0.09
PE Ratio	n/a
Forward PE	30.30
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,289,125
Open	5.58
Previous Close	5.58
Day's Range	5.21 - 5.61
52-Week Range	3.30 - 6.75
Beta	0.71
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 25, 2024

About VNDA

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bi...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 12, 2006
• Employees: 203
• Stock Exchange: NASDAQ
• Ticker Symbol: VNDA

Financial Performance

In 2023, VNDA's revenue was $192.64 million, a decrease of -24.27% compared to the previous year's $254.38 million. Earnings were $2.51 million, a decrease of -60.02%.